SLC5A2 and cardiovascular disorder: Although there is growing clinical data to support the use of SGLT-2 inhibitors in cardiovascular disease in general, the biochemical mechanism is not fully understood, and the sex-specific response to SGLT-2 inhibitors remains underrepresented in the literature [29].